EUVIMEDEUVIMED entdecken
Crossref

Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds

Faraz Kazmi, Ulrike Gradhand, Eric T Gangl, Robert Fricke, Tanya Aldinger, Rob Chambers, Massimiliano Donzelli, Douglas Ferguson, Bernard G Francq, Paul J Harradine, Rémi Kazma, Saro Mardirosian und 10 weitere

Drug Metabolism and Disposition · 2026

DOI: 10.1016/j.dmd.2026.100358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Faraz Kazmi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: fkazmi@its.jnj.com. Hauptthemen laut MEDLINE: Blood Proteins. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The reliable measurement of plasma protein binding (PPB) is crucial for understanding drug pharmacokinetics and predicting drug-drug interactions (DDIs). Historically, regulatory guidelines had imposed a cutoff of 1% for the unbound fraction (fu) of highly bound drugs, leading to concerns about overestimating DDI risks and triggering unnecessary clinical DDI trials. In this study, an IQ working group comprising 11 member companies evaluated the interlab accuracy and precision of the PPB determination of 20 compounds highly bound to plasma proteins with fu values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood ProteinsProtein BindingDrug InteractionsHumansPharmaceutical PreparationsReproducibility of ResultsCytochrome P-450 Enzyme SystemDialysis

Stichwörter der Autor:innen

Drug-drug interaction risk assessmentEquilibrium dialysisICH M12Plasma P450 IC(50) shift methodPlasma protein bindingUnbound fraction

Substanzen

Blood ProteinsPharmaceutical PreparationsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: fkazmi@its.jnj.com.
  • NCE Drug Metabolism & Pharmacokinetics, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Clinical Pharmacology Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts.
  • In vitro ADME, Preclinical Development, Bayer AG, Wuppertal, Germany.
  • DMPK, GSK, Collegeville, Pennsylvania.
  • DMPK, GSK, Stevenage, Hertfordshire, UK.

Zitieren

APA

Kazmi, F., Gradhand, U., Gangl, E. T., Fricke, R., Aldinger, T., Chambers, R., Donzelli, M., Ferguson, D., Francq, B. G., Harradine, P. J., Kazma, R., Mardirosian, S., Nicolas, J. M., Shinkyo, R., Simon, S., Sinz, M., Stuart, P., Tatikola, K., Wittwer, M. B., …, & Kalvass, J. C. (2026). Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100358

Vancouver

Kazmi F, Gradhand U, Gangl ET, Fricke R, Aldinger T, Chambers R, et al. Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100358

BibTeX
@article{Kazmi2026,
  author = {Kazmi, Faraz and Gradhand, Ulrike and Gangl, Eric T and Fricke, Robert and Aldinger, Tanya and Chambers, Rob and Donzelli, Massimiliano and Ferguson, Douglas and Francq, Bernard G and Harradine, Paul J and Kazma, Rémi and Mardirosian, Saro and Nicolas, Jean-Marie and Shinkyo, Raku and Simon, Sandrine and Sinz, Michael and Stuart, Patricia and Tatikola, Kanaka and Wittwer, Matthias Beat and Vendrell-Navarro, Gloria and Yan, Zhengyin and Kalvass, John C},
  title = {Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  doi = {10.1016/j.dmd.2026.100358}
}
Kostenlos starten →